Compare · CTNM vs NVO
CTNM vs NVO
Side-by-side comparison of Contineum Therapeutics Inc. (CTNM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTNM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $212.85B, about 401.2x CTNM ($530.5M).
- Over the past year, CTNM is up 242.0% and NVO is down 29.9% - CTNM leads by 271.9 points.
- CTNM has been more active in the news (10 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 5 for CTNM).
- Company
- Contineum Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $14.14+5.80%
- $48.01+0.82%
- Market cap
- $530.5M
- $212.85B
- 1M return
- +5.21%
- +7.74%
- 1Y return
- +241.96%
- -29.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 10
- 4
- Recent ratings
- 5
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CTNM
- SEC Form 4 filed by Director Miralles Gines Diego
- SEC Form 4 filed by Director Lyons-Williams Lori
- SEC Form 4 filed by Director Ware Olivia C
- SEC Form 4 filed by Director Schimmelpennink Evert B.
- SEC Form 4 filed by Director Ignelzi Troy A.
- SEC Form 4 filed by Director Brady Todd R.
- SEC Form 4 filed by Director Boyce Sarah
- Contineum Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Scientific Officer Lorrain Daniel S. sold $54,862 worth of shares (4,170 units at $13.16) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 139,372 units (SEC Form 4)
- Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S